U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612215) titled 'Elacestrant in Advanced Triple Positive Breast Cancer' on May 21.
Brief Summary: The purpose of this study to assess the safety and efficacy of elacestrant, a selective estrogen receptor degrader (SERD) and dual biologic therapy, trastuzumab and pertuzumab, in patients with triple-positive breast cancer with and without an ESR1 mutation.
Study Start Date: May 13
Study Type: INTERVENTIONAL
Condition:
ER Positive, HER2 Positive Breast Cancer
Intervention:
DRUG: Elacestrant
Elacestrant will be administered orally once daily at a dose of 345 mg daily.
DRUG: Trastuzumab
Initial dose of trastuzumab is 8 mg/kg administered as a 90-...